Fenofibrate/Rosuvastatin

非诺贝特/瑞舒伐他汀

Report date: 2022/07/06 17:25:40

Base Information

Drug NameFenofibrate/Rosuvastatin
Drug Alias Name瑞舒伐他汀和非诺贝特Rosuvastatin Calcium/Fenofibrate瑞舒伐他汀•非诺贝特Rosuvastatin Calcium/FenomaxRosuvastatin and Fenofibrate +[12] 
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator activated receptor agonistsHMG-CoA reductase inhibitors
TargetsPeroxisome proliferator activated receptorHMG-CoA reductase
Therapy Area/IndicationsDyslipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes FenofibrateRosuvastatin Calcium
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIldong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesIldong Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDyslipidemias

Other Information

ATC CodeN/A
Related LinksN/A